10-Q: GoodRx Holdings Reports Mixed Q2 Results Amidst Pharmacy Landscape Shifts

GoodRx Holdings, Inc. announced a 6% increase in revenue for the second quarter of 2024, alongside a decrease in net income compared to the same period last year, while navigating a changing retail pharmacy environment.

Summary

• GoodRx Holdings, Inc. reported a 6% increase in revenue to $200.6 million for the second quarter of 2024, compared to $189.7 million in the same period of 2023.
• Net income for the quarter was $6.7 million, a significant decrease from $58.8 million in the second quarter of 2023.
• Adjusted EBITDA increased to $65.4 million, with an Adjusted EBITDA Margin of 32.6%, compared to $53.5 million and 28.2% respectively in the prior year.
• The company experienced a 7% increase in revenue to $398.5 million for the first six months of 2024, compared to $373.7 million in the same period of 2023.
• Net income for the first six months of 2024 was $5.7 million, down from $55.5 million in the first six months of 2023.
• Adjusted EBITDA for the first six months of 2024 was $128.2 million, with an Adjusted EBITDA Margin of 32.2%, compared to $106.7 million and 28.6% respectively in the prior year.
• The company noted the impact of recent retail pharmacy closures, particularly Rite Aid, which are expected to have a mid-single-digit million dollar impact on prescription transactions revenue in the second half of 2024.
• GoodRx also highlighted potential renegotiations between pharmacies and PBMs due to pharmacies' increased focus on rationalizing spending, which may impact prescription transactions revenue.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive revenue growth but significant declines in net income and challenges in the subscription business. The ongoing legal issues and changing pharmacy landscape add to the uncertainty, resulting in a neutral to slightly negative sentiment.

Positives

• Prescription transactions revenue increased by 7% year-over-year, driven by an 8% increase in Monthly Active Consumers.
• Pharma manufacturer solutions revenue increased by 9% year-over-year, indicating growth in this segment.
• Adjusted EBITDA and Adjusted EBITDA Margin showed improvement compared to the same period last year.
• The company has a strong cash position with $524.9 million in cash and cash equivalents as of June 30, 2024.
• GoodRx has extended the maturity date on $88 million of its revolving credit facility to April 10, 2029.

Negatives

• Net income decreased significantly in both the second quarter and first six months of 2024 compared to the same periods in 2023.
• Subscription revenue decreased by 8% year-over-year due to the sunset of the Kroger Savings program.
• The company expects a mid-single-digit million dollar impact on prescription transactions revenue in the second half of 2024 due to retail pharmacy closures.
• The company is facing ongoing legal proceedings, including class action lawsuits related to privacy and securities matters.
• There is a potential impact on prescription transactions revenue due to heightened renegotiations between pharmacies and PBMs.

Risks

• The company is exposed to risks related to changes in the U.S. retail pharmacy landscape, including store closures and renegotiations between pharmacies and PBMs.
• There are risks associated with the company's reliance on a limited number of industry participants, including PBMs, pharmacies, and pharma manufacturers.
• The company faces risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cybersecurity.
• The company is subject to litigation risks, including class action lawsuits related to privacy and securities matters.
• There are risks related to the company's debt arrangements, including the new $500 million term loan.

Future Outlook

The company expects the recent retail pharmacy closures to have a mid-single-digit million dollar impact on prescription transactions revenue in the second half of 2024. They also anticipate heightened renegotiations between pharmacies and PBMs, which may impact revenue. GoodRx expects pharma manufacturer solutions to continue to grow as a percentage of total revenue in the near to medium term.

Management Comments

• The company is navigating a rapidly changing U.S. retail pharmacy landscape.
• GoodRx is focused on expanding its integrated savings program.
• The company is working to scale and expand available services, capabilities and platforms of its pharma manufacturer solutions offering.

Industry Context

The report highlights the significant shifts occurring in the U.S. retail pharmacy landscape, with store closures and increased focus on cost rationalization by pharmacies. This is impacting GoodRx's prescription volume and revenue, and is likely to lead to increased negotiations between pharmacies and PBMs. These changes are creating both challenges and opportunities for companies like GoodRx that operate in the prescription savings space.

Comparison to Industry Standards

• GoodRx's revenue growth of 6% in Q2 2024 is moderate compared to some high-growth tech companies in the healthcare sector, but is in line with other established players in the digital health space.
• The decrease in net income is a concern, and will need to be addressed in future quarters. This is in contrast to some competitors who have been able to maintain or increase profitability.
• The Adjusted EBITDA margin of 32.6% is a positive sign, indicating that the company is managing its costs effectively. This is comparable to other companies in the digital health space with similar business models.
• The decline in subscription plans due to the sunset of the Kroger Savings program is a setback, and the company will need to focus on growing its other subscription offerings to compensate. This is a challenge faced by many subscription-based businesses.
• The company's ongoing legal proceedings are a risk factor that is not unique to GoodRx, as many companies in the tech and healthcare sectors face similar challenges. However, the potential financial impact of these proceedings is a concern.

Legal Proceedings

• The company is involved in multiple class action lawsuits related to privacy and securities matters.
• A settlement agreement has been proposed in one of the class action lawsuits, but it is subject to final court approval.
• The company is also involved in an arbitration matter related to a breach of contract.

Related Party Transactions

• The company repurchased 20.9 million shares of Class A common stock from related parties for $151.4 million.

Stakeholder Impact

• Shareholders are impacted by the decrease in net income and the ongoing legal proceedings.
• Employees may be affected by the restructuring and cost reduction efforts.
• Customers may experience changes in the availability of discounted pricing due to the changing retail pharmacy landscape.
• Suppliers and creditors may be impacted by the company's financial performance and debt arrangements.

Next Steps

• The company will need to manage the impact of retail pharmacy closures on prescription transactions revenue.
• GoodRx will need to address the decline in subscription plans and focus on growing its other subscription offerings.
• The company will need to navigate the potential renegotiations between pharmacies and PBMs.
• GoodRx will need to continue to scale and expand its pharma manufacturer solutions offering.
• The company will need to defend against ongoing legal proceedings.

Key Dates

Keywords

prescription transactions, pharmacy benefit managers, PBMs, subscription revenue, pharma manufacturer solutions, retail pharmacy, Adjusted EBITDA, legal proceedings, stock repurchase, debt, healthcare, digital health